World · India Bureau
Scientists identify fresh TB drug targets to combat resistant strains
Researchers at CSIR-CCMB have pinpointed new therapeutic avenues against tuberculosis, offering potential solutions to growing drug resistance. The breakthrough comes as the disease continues to pose significant public health challenges across the region.
LSN India ·
Tuberculosis remains one of South Asia's most pressing health concerns, with treatment protocols typically requiring multiple antibiotics administered over several months. The emergence of drug-resistant strains has significantly complicated clinical management, necessitating fresh approaches to disease control.
Scientists at the Council of Scientific and Industrial Research's Centre for Cellular and Molecular Biology (CSIR-CCMB) have identified novel molecular targets that could enhance tuberculosis treatment strategies. These potential targets represent a significant step forward in addressing the evolving threat posed by resistant variants of Mycobacterium tuberculosis.
The research underscores the critical need for innovative pharmaceutical interventions as conventional antibiotic regimens face mounting efficacy challenges. Drug-resistant tuberculosis, including multidrug-resistant and extensively drug-resistant forms, has become increasingly prevalent across the region, complicating patient outcomes and straining healthcare resources.
The identification of new therapeutic targets offers promise for developing improved treatment options that could reduce patient burden and improve cure rates. Researchers emphasize that such discoveries are essential components of comprehensive strategies to control tuberculosis transmission and achieve public health goals in India and neighboring countries.